Kuala Lumpur, 14 February 2020 – Sime Darby Oils (SDO) and Universiti Kebangsaan Malaysia (UKM) collaborate for Clinical Trial to Treat Fatty Liver Disease. It’s the world’s first comprehensive clinical trial to determine if the palm oil derived Tocotrienols, an antioxidant in the vitamin E family, could be used as a therapeutic approach for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
A Memorandum of Agreement (MoA) for the collaboration which is expected to run for 2 years was signed by SDO’s Managing Director, Mohd Haris Mohd Arshad and UKM’s Dean of Faculty of Medicine and Professor of Medicine, Professor Dr. Raja Affendi Raja Ali, representing UKM’s official signatory to the MOA, Vice Chancellor, Professor Dato’ Ir Dr Mohd Hamdi Bin Abd Shukor. The parties are expecting to see preliminary results within six (6) months from the commencement of the clinical trial this month and a full publication of the findings in 2021.
NAFLD is a common disorder affecting non-alcohol consumers and refers to a group of conditions involving the accumulation of excess fat in the liver. Early-stage NAFLD does not usually cause any harm. But if left untreated, it can lead to serious liver damage, including cirrhosis, a disease in which the liver does not function properly due to long-term replacement of normal liver tissues with scar tissues.
Professor Dr Raja Affendi, a Consultant Physician in Gastroenterology & Hepatology at the Hospital Canselor Tuanku Muhriz & UKM Specialist Centre, who is also the lead investigator of the clinical trial said, that the prevalence of NAFLD in Malaysia could be approximately 15-30% of the general adult population. This projection is based on the high prevalence of other metabolic diseases in the Malaysian population that are commonly associated with NAFLD, such as high blood sugar, hypertension, and obesity. About 60% of Malaysian with slightly elevated cholesterol levels have NAFLD, and yet, no medication is available for the disease.
The Tocotrienols that will be used in the clinical trial studies are extracted from palm fruit (Elaeis Guineensis) harvested exclusively from the plantations of Sime Darby Plantation (SDP), the world’s largest producer of Certified Sustainable Palm Oil (CSPO). SDP together with the Malaysian Palm Oil Board (MPOB) pioneered the palm Tocotrienols extraction process in 1993. SDO currently produces a Tocotrienol supplement called NATRIÉO, which has been made commercially available by the company since 2002.
Earlier studies had shown that Tocotrienols is a powerful antioxidant and is effective in reducing arterial blockage, lowering bad cholesterols and preventing a variety of ageing-related disorders due to reduced free radicals and DNA damage, among others.